

Variant: *NM_003159.2(CDKL5):c.119C>T (p.Ala40Val)*

Version: 1.0

CA121521 [↗](#)

11502 (ClinVar) [↗](#)

Gene: CDKL5 ([HGNC:6792](#))

Condition: CDKL5 disorder ([MONDO:0100039](#))

Inheritance Mode: X-linked inheritance

UUID: 0e323081-868b-43b4-974c-8893a942d274

Approved on: 2021/3/30

Published on: 2021/5/17

HGVS expressions

NM_003159.2:c.119C>T

NM_003159.2(CDKL5):c.119C>T (p.Ala40Val)

NC_000023.11:g.18564496C>T

CM000685.2:g.18564496C>T

NC_000023.10:g.18582616C>T

CM000685.1:g.18582616C>T

NC_000023.9:g.18492537C>T

NG_008475.1:g.143892C>T

ENST00000623535.2:c.119C>T

ENST00000635828.1:c.119C>T

ENST00000637881.1:c.119C>T

ENST00000674046.1:c.119C>T

ENST00000379989.6:c.119C>T

ENST00000379996.7:c.119C>T

ENST00000463994.4:c.119C>T

ENST00000623364.3:c.119C>T

ENST00000623535.1:c.119C>T

ENST00000624700.3:c.119C>T

NM_001037343.1:c.119C>T

NM_001323289.1:c.119C>T

NM_001323289.2:c.119C>T

NM_001037343.2:c.119C>T

NM_003159.3:c.119C>T

Pathogenic

Met criteria codes **5**

PM1

PS4

PS2_Very Strong

PP3

PM2_Supporting

Evidence Links **0**

Expert Panel

[Rett and Angelman-like Disorders VCEP](#) [↗](#)

Criteria Specification Information **!**

[↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel

Rett and Angelman-like Disorders VCEP

The p.Ala40Val variant in CDKL5 has been reported in at least 4 unconfirmed de novo occurrences in patients with CDKL5 disorder (PMID 27779742, 17993579, 22678952, 19793311) (PM6_VS). It is also reported in the mosaic state in a male patient with CDKL5 disorder (PMID 25819767) and therefore confirmed to be de novo (PS2). The p.Ala40Val variant has been observed in at least 10 other individuals with CDKL5 disorder (27779742, 25819767, 17993579, 22678952, 19793311, 21309761, 19780792) (PS4). The variant is absent in gnomAD (PM2_supporting). The variant is located in a well-characterized (ATP binding region: aa 19-43) functional domain of CDKL5 (PMID: 28544139, 17993579, 23064044, 29264392) (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Ala40Val in CDKL5 is classified as Pathogenic based on the ACMG/AMP criteria (PM6_very strong, PS2, PS4_strong, PM1, PM2_supporting, PP3).

Met criteria codes

PM1			The variant is located in a critical domain of CDKL5 (ATP binding region: aa 19-43)(PMID: 28544139,17993579) (PM1)
PS4			PS4_S: The p.Ala40Val variant has been observed in at least 10 other individuals with CDKL5 disorder (27779742, 25819767, 17993579, 22678952, 19793311, 21309761, 19780792)
PS2_Very Strong			Reported in the mosaic state in a male patient with CDKL5 disorder (PMID 25819767) and therefore confirmed to be de novo (PS2). PM6_VS: The p.Ala40Val variant in CDKL5 has been reported in at least 4 unconfirmed de novo occurrences in patients with CDKL5 disorder (PMID 27779742, 17993579, 22678952, 19793311). While the cases involved did not have parental relationships confirmed (PM6), they did reach the very strong threshold for this type of evidence as defined by the Rett/AS VCEP, and this criterion is being used as a proxy since PM6_very strong is not currently available.
PP3			Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3)
PM2_Supporting			The p.Ala40Val variant is absent in gnomAD and ExAC (PM2_supporting)

Curation History



 ▾

 ▾

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.

[ClinGen Terms of Use.](#)

⌘ [Powered by BCM's Genboree.](#)